Prophylaxis and Treatment of Cancer-Associated Venous Thromboembolism - Comparison Hematologist/Oncologists versus Angiologist/Phlebologists

被引：0
|
作者：
Matzdorff, Axel [1 ]
Ledig, Bettina [2 ]
Stuecker, Markus [3 ]
Riess, Hanno [4 ]
机构：
[1] Asklepios Clin Uckermark, Dept Internal Med 2, Auguststr 23, D-16303 Schwedt Od, Germany
[2] LEO Pharma GmbH, Neu Isenburg, Germany
[3] Ruhr Univ Bochum, St Josef Hosp, Dept Dermatol, Bochum, Germany
[4] Charite Campus Virchow Clin, Med Clin Haematol Oncol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 03期
关键词：
Cancer-associated venous thromboembolism; Health services research; Hematologist; Oncologist; Angiologist Phlebologist; CLINICAL-PRACTICE GUIDELINES; DEEP-VEIN THROMBOSIS; ADHERENCE; RISK;
D O I：
10.1159/000456670
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：138 / 140
页数：3
相关论文
共 50 条
  • [21] Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
    Coleman, Craig, I
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Brobert, Gunnar
    Cohen, Alexander T.
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y.
    Ekbom, Anders
    Carrier, Marc
    BLOOD, 2022, 140 : 11368 - 11369
  • [22] Edoxaban for Cancer-Associated Venous Thromboembolism
    Frere, Corinne
    Dufilho, Monique
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 94 - 94
  • [23] Rivaroxaban for cancer-associated venous thromboembolism
    Liang, Bo
    Liang, Yi
    Zhao, Li-Zhi
    Zhao, Yu-Xiu
    Gu, Ning
    SCIENCE PROGRESS, 2021, 104 (02)
  • [24] Incidence of cancer-associated venous thromboembolism
    Ballardini, P.
    Zangirolami, A.
    Margutti, G.
    Manfredini, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI70 - XI71
  • [25] Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism ― A Retrospective Observational Study ―
    Goto, Hitoshi
    Umetsu, Michihisa
    Akamatsu, Daijirou
    Sugawara, Hirofumi
    Tsuchida, Ken
    Yoshida, Yoshitaro
    Suzuki, Shunya
    Kamei, Takashi
    CIRCULATION JOURNAL, 2024, 88 (02) : 251 - 258
  • [26] Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
    Yhim, Ho-Young
    Bang, Soo-Mee
    BLOOD RESEARCH, 2014, 49 (02) : 77 - 79
  • [27] Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?
    Grilusova, Kristina
    Bolek, Tomas
    Skornova, Ingrid
    Stanciakova, Lucia
    Mikusova, Veronika
    Kubisz, Peter
    Galajda, Peter
    Stasko, Jan
    Samos, Matej
    Mokan, Marian
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (02) : E212 - E218
  • [28] Cancer-associated venous thromboembolism: Risk assessment, prevention, and treatment
    Feistritzer C.
    memo - Magazine of European Medical Oncology, 2013, 6 (3) : 197 - 201
  • [29] Cancer-associated venous thromboembolism—Pathogenesis, diagnosis, prevention and treatment
    Riess H.
    best practice onkologie, 2020, 15 (10) : 448 - 455
  • [30] New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
    den Exter, Paul L.
    Kooiman, Judith
    van der Hulle, Tom
    Huisman, Menno V.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 163 - 169
12345